July 12, 2018 06:01 AM EDT
Pharma

Gen­mab puts down $54M for im­munother­a­py col­lab­o­ra­tion — ready to spend mil­lions more

Amber Tong

Af­ter fill­ing its pipeline with Big Phar­ma-part­nered an­ti­body ther­a­peu­tics, J&J dar­ling Gen­mab has turned to a fel­low Eu­ro­pean biotech for its lat­est for­ay in­to can­cer …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: Am­gen obe­si­ty shot shows 20% weight loss, but dos­ing ques­tions hang over read­out

Up­dat­ed: Roche buys out CAR-T part­ner Po­sei­da for $1B up­front

Alec­tor says Alzheimer's pro­gram tar­get­ing mi­croglia fails Phase 2, stock dives

Sarep­ta li­cens­es Ar­row­head­'s RNA-based rare dis­ease pipeline, promis­ing big biobucks

Roche’s TIG­IT drug miss­es last shot at sur­vival end­point win in Phase 3 lung can­cer tri­al

How did Trump’s FDA pick land? Biotech stocks are up, and ex­ec­u­tives are (most­ly) re­lieved

A service from the Financial Times